ArticleFrontiers in neurology2025
Construction and validation of a nomogram for predicting 3-month outcome in elderly patients with nonvalvular atrial fibrillation-induced acute ischemic stroke.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: Cardiogenic embolism caused by atrial fibrillation (AF) leads to higher disability, mortality, and recurrence rates compared to stroke independent of AF, resulting in a poorer prognosis for patients. Effective risk assessment and timely clinical intervention are essential. This study aimed to develop and validate a personalized nomogram to predict the 3-month outcomes for elderly patients with nonvalvular atrial fibrillation (NVAF) induced acute ischemic stroke (AIS). Methods: A retrospective cohort study was implemented at Hefei First People's Hospital. Participants were patients diagnosed with NVAF-induced acute ischemic stroke (NVAF-AIS) who fulfilled the study's inclusion criteria. Data collection encompassed baseline demographic, clinical, and laboratory information. The primary endpoint was the 3-month outcome, evaluated using the modified Rankin Scale (mRS). To identify potential predictors, univariate logistic regression and the least absolute shrinkage and selection operator (LASSO) regression algorithm were employed. Subsequently, a binary regression model was established, and internal validation was conducted using bootstrap resampling with 1,000 iterations. The assessment tools included receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA). Ultimately, a nomogram was constructed to forecast the 3-month outcomes for this demographic. Results: A total of 178 patients were included, of whom 95 (53.3%) had a poor outcome (mRS > 2). Independent risk factors for poor outcomes in NVAF-AIS patients included stroke history (OR = 9.140; 95% CI: 3.481-26.923), NIHSS score (OR = 1.167; 95% CI: 1.071-1.284), glycated hemoglobin (HbA1c) (OR = 2.211; 95% CI:1.573-3.220), D-dimer (OR = 1.157; 95% CI: 1.022-1.361), neutrophil-to-lymphocyte ratio (NLR) (OR = 1.531; 95%CI:1.242-1.972), and left atrial diameter (LAD) (OR = 1.163; 95%CI: 1.072-1.280). A nomogram was created based on these factors. The area under the ROC curve (AUC) for the nomogram was 0.933 (95%CI:0.897-0.969) before and 0.933(95%CI:0.895-0.964) after internal validation, demonstrating good discriminative ability. The nomogram also showed excellent calibration and clinical applicability, as confirmed by calibration curve analysis and DCA. Conclusion: Stroke history, NIHSS score, HbA1c, D-dimer, NLR, and LAD are independent risk factors for poor outcomes in elderly patients with NVAF-AIS. The nomogram, integrating these factors, provides intuitive, individualized predictions for the risk of poor outcomes, aiding in the selection of treatment options for these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.